SCHEDULE: Farallon Capital Boosts Tango Therapeutics Stake

Farallon Capital and its affiliated entities have disclosed a collective beneficial ownership of 8.4% in Tango Therapeutics, Inc. common stock.

Summary

• Farallon Capital, through various funds and managing members, collectively holds 9,157,000 shares of Tango Therapeutics, Inc. common stock.
• This aggregate ownership represents 8.4% of the total outstanding common stock of Tango Therapeutics, Inc.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating an update to a previously reported ownership position.
• The reporting group includes Farallon Capital Partners, L.P., Farallon Capital Institutional Partners, L.P., Farallon Capital Offshore Investors II, L.P., and several other affiliated funds and general partners.
• Individual managing members and senior managing members of Farallon's general partners, including Joshua J. Dapice, Philip D. Dreyfuss, and Hannah E. Dunn, are deemed to have shared voting and dispositive power over the 9,157,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as a significant institutional investor maintains or increases its stake, indicating continued confidence in the company. However, as a passive ownership disclosure, it does not provide operational or financial performance insights.

Positives

• A significant stake by a prominent institutional investor like Farallon Capital may signal confidence in Tango Therapeutics' long-term prospects.
• The continued or increased ownership by Farallon Capital could attract further institutional interest in Tango Therapeutics.

Negatives

• The filing does not provide specific reasons for the ownership change or any forward-looking statements from Farallon Capital regarding their investment strategy.

Risks

• The beneficial ownership percentage could change in the future, potentially impacting market perception.
• The filing does not indicate any intent to influence or change control of the issuer, which means Farallon Capital's role is currently passive.

Future Outlook

NA

Industry Context

This filing reflects a standard disclosure of significant passive ownership by an institutional investment firm in a publicly traded biotechnology company. Such disclosures are common and provide transparency into major shareholder positions, which can influence market sentiment and liquidity.

Stakeholder Impact

• Shareholders: Increased institutional ownership can provide stability and potentially attract more investors, but also means a larger block of shares is controlled by a single entity.
• Management: Awareness of a significant passive investor on the shareholder register.

Key Dates

Keywords

Tango Therapeutics, Farallon Capital, Institutional Ownership, SEC Filing, Schedule 13G, Common Stock, Beneficial Ownership, Biotechnology, Investment Fund